Dr. Chris Parker: Radium–223 Will Change Practice in Metastatic Prostate Cancer
Dr. Chris Parker: Radium–223 Will Change Practice in Metastatic Prostate Cancer
Interview by L Scott Zoeller
20110914
2011 Oct 14
OncologySTAT Editorial Team
Dr. Chris Parker: Radium–223 Will Change Practice in Metastatic Prostate Cancer
OncologySTAT Editorial Team. 2011 Oct 14, Interview by L Scott Zoeller
Abstract
Dr. Parker is consultant in Clinical Oncology at the Royal Marsden Hospital and Honorary Senior Lecturer in Prostate Cancer Translational Research at the Institute of Cancer Research, Sutton, United Kingdom. OncologySTAT: What is the mechanism of action for radium-223, and how it is administered?Dr. Parker: The mechanism of action is very simple. Radium, chemically speaking, is just like calcium. They are both in the same group of the periodic table. In the same way that calcium localizes to bone,...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
